Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/126481
Author(s): Ribeiro AS
Nobre AR
Mendes N
Almeida J
Vieira AF
Sousa B
Carvalho F
Monteiro J
Polónia A
Fonseca M
Sanches J
Santos N
Seruca R
Paredes J
Title: SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells
Publisher: BMC
Issue Date: 2018
Abstract: BACKGROUND: Basal-like breast cancer (BLBC) is a poor prognosis subgroup of triple-negative carcinomas that still lack specific target therapies and accurate biomarkers for treatment selection. P-cadherin is frequently overexpressed in these tumors, promoting cell invasion, stem cell activity and tumorigenesis by the activation of Src-Family kinase (SRC) signaling. Therefore, our aim was to evaluate if the treatment of BLBC cells with dasatinib, the FDA approved SRC inhibitor, would impact on P-cadherin induced tumor aggressive behavior. METHODS: P-cadherin and SRC expression was evaluated in a series of invasive Breast Cancer and contingency tables and chi-square tests were performed. Cell-cell adhesion measurements were performed by Atomic Force Microscopy, where frequency histograms and Gaussian curves were applied. 2D and 3D cell migration and invasion, proteases secretion and self-renew potential were evaluated in vitro. Student's t-tests were used to determine statistically significant differences. The cadherin/catenin complex interactions were evaluated by in situ proximity-ligation assay, and statistically significant results were determined by using Mann-Whitney test with a Bonferroni correction. In vivo xenograft mouse models were used to evaluate the impact of dasatinib on tumor growth and survival. ANOVA test was used to evaluate the differences in tumor size, considering a confidence interval of 95%. Survival curves were estimated by the Kaplan-Meier's method, using the log-rank test to assess significant differences for mice overall survival. RESULTS: Our data demonstrated that P-cadherin overexpression is significantly associated with SRC activation in breast cancer cells, which was also validated in a large series of primary tumor samples. SRC activity suppression with dasatinib significantly prevented the in vitro functional effects of P-cadherin overexpressing cells, as well as their in vivo tumorigenic and metastatic ability, by increasing mice overall survival. Mechanistically, SRC inhibition affects P-cadherin downstream signaling, rescues the E-cadherin/p120-catenin complex to the cell membrane, recovering cell-cell adhesion function. CONCLUSIONS: In conclusion our findings show that targeting P-cadherin/SRC signaling and functional activity may open novel therapeutic opportunities for highly aggressive and poor prognostic basal-like breast cancer.
Subject: Basal-like breast cancer
Dasatinib
P-cadherin
Src family kinase
URI: https://hdl.handle.net/10216/126481
Source: Cell communication and signaling : CCS, vol.16(1), p. 75
Related Information: info:eu-repo/grantAgreement/FCT/COMPETE/132983/PT
info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBPD%2F75705%2F2011/PT
info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBPD%2F90303%2F2012/PT
Document Type: Artigo em Revista Científica Internacional
Rights: openAccess
License: https://creativecommons.org/licenses/by/4.0/
https://creativecommons.org/publicdomain/zero/1.0/
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.1186-s12964-018-0286-2.pdf14.16 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons